Barman Diabetes Specialities Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.20 M
- Revenue Growth 8.98%
- Profit Growth 32.28%
- Ebitda 32.59%
- Net Worth 11.59%
- Total Assets 12.31%
About Barman Diabetes Specialities
Barman Diabetes Specialities Private Limited (BDSPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 August 2005 and has a history of 19 years and five months. Its registered office is in Assam, Assam.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.20 M.
Tulika Barman, Karuna Barman, and Durga Barman serve as directors at the Company.
Company Details
- Location Assam, Assam
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85120AS2005PTC007863
-
Company No.
007863
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Aug 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Barman Diabetes Specialities?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tulika Barman
|
Director | 31-Aug-2005 | Current |
|
Karuna Barman
|
Director | 31-Aug-2005 | Current |
|
Durga Barman
|
Director | 31-Aug-2005 | Current |
Financial Performance of Barman Diabetes Specialities.
Barman Diabetes Specialities Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.98% increase. The company also saw a substantial improvement in profitability, with a 32.28% increase in profit. The company's net worth Soared by an impressive increase of 11.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Barman Diabetes Specialities?
In 2020, Barman Diabetes Specialities had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.20 M
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 0.32 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Sep 2005 | Uco Bank | ₹3.20 M | Open |
How Many Employees Work at Barman Diabetes Specialities?
Unlock and access historical data on people associated with Barman Diabetes Specialities, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Barman Diabetes Specialities, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Barman Diabetes Specialities's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.